Villejuif

• Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended
  2024-513977-31-00 4 2019-07-17 Untreated squamous cell carcinoma of the head and neck
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended
  2023-508207-21-00 9 2019-02-08 Advanced Malignant Tumors
• Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended
  2023-503554-12-00 9 2019-01-09 lung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer;
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• Olaparib Monotherapy in HRRm or HRD Positive Cancer Ended
  2022-500797-34-00 4 2018-12-17 Treatment of participants with positive cancer for HRRm or HRD.
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo … Ended
  2024-514586-20-01 5 2018-05-02 Non small cell lung cancer
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended
  2023-510296-56-00 5 2018-03-26 Advanced Urothelial Cancer
• Safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer Ended
  2024-517439-39-00 7 2018-03-19 Metastatic castration-resistant prostate cancer.
• A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat … Ended
  2024-510634-41-00 4 2018-02-22 Recurrent, metastatic, or persistent Cervical Carcinoma
• A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tu … Ended
  2024-514437-37-00 1 2018-02-22 Advanced Hepatocellular Carcinoma (HCC) that is not amenable to transp
• Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid … Ended
  2024-511916-25-00 7 2017-09-04 Advanced Solid Tumors
• ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) a … Ended
  2024-514920-18-00 9 2017-06-20 Metastatic squamous cell carcinoma of head and neck, lung, esophagus,
• CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended
  2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
• A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab ( … Ended
  2024-515000-39-00 9 2017-01-17 Recurrent glioblastoma.
• ROLLOVER STUDY FOR TAZEMETOSTAT Ended
  2023-510553-41-00 9 2016-08-29 Subjects will receive tazemetostat as dictated in their antecedent stu
• A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor … Ended
  2022-500400-22-00 5 2016-06-23 Hodgkin lymphoma

Showing 913–936 of 961 trials